本頁面由Tiger Trade Technology Pte. Ltd.提供服務

IN8bio, Inc.

1.98
+0.11005.88%
成交量:3.87萬
成交額:7.55萬
市值:1,949.72萬
市盈率:-0.45
高:2.06
開:1.89
低:1.85
收:1.87
52周最高:7.50
52周最低:1.17
股本:984.71萬
流通股本:915.07萬
量比:1.89
換手率:0.42%
股息:- -
股息率:- -
每股收益(TTM):-4.4441
每股收益(LYR):-4.4441
淨資產收益率:-92.49%
總資產收益率:-46.64%
市淨率:0.71
市盈率(LYR):-0.45

資料載入中...

公司資料

公司名字:
IN8bio, Inc.
交易所:
NASDAQ
成立時間:
2016
員工人數:
17
公司地址:
350 5th Avenue,Suite 5330,New York,New York,United States
郵編:
10118
電話:
傳真:
- -
簡介:
In8bio, Inc.於2016年2月8日在百慕大註冊成立。該公司是一家領先的臨床階段生物製藥公司,專註於癌症和自身免疫性疾病的gamma-delta T細胞治療候選產品和gamma-delta T細胞接合劑的發現、開發和商業化。

董事

名稱
職位
Alan S. Roemer
Chairman of the Board
William Ho
President,Chief Executive Officer and Director
Corinne Epperly
Independent Director
Emily T. Fairbairn
Independent Director
Jeremy Graff
Independent Director
Luba Greenwood
Independent Director
Peter Brandt
Independent Director

股東

名稱
職位
William Ho
President,Chief Executive Officer and Director
Kate Rochlin
Chief Operating Officer and President
Patrick McCall
Chief Financial Officer
Lawrence Lamb
Executive Vice President, Chief Scientific Officer and Co-Founder